Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening hyperinflammatory/hypercytokinemia syndrome clinicopathologically manifested by fever, hepatosplenomegaly, cytopenias, liver dysfunction, and hemophagocytosis.
Methods
We searched the medical literature for English-written articles and analyzed data regarding the diagnosis, pathoetiology, prognosis, and management of HLH.
Results
HLH can be subcategorized into primary/genetic (PHLH) or secondary/acquired (SHLH) according to etiology. PHLH, including familial HLH and inherited immune deficiency syndromes, typically occurs in children harboring underlying genetic defects, whereas SHLH frequently manifests in adults and is associated with infection, autoimmunity, immune suppression, or malignancy. The pathogenesis of HLH is still elusive. Its known mechanisms include somatic mutations in gene coding for proteins implicated in the cytotoxic pathways of cytotoxic T or natural killer cells. The impaired ability of these cells to kill target cells leads to an uncontrolled hypercytokinemia and hyperinflammatory process, triggering hemophagocytosis and multiorgan failure. Corticosteroids, chemotherapy, and immunotherapy are the mainstay therapeutic strategies. The consolidation with allogeneic hematopoietic stem cell transplantation is a potentially curative option for PHLH and refractory or relapsed SHLH.
Conclusions
Understanding of the pathophysiology of HLH has improved in the last decade. The establishment of diagnostic and treatment guidelines for PHLH and SHLH has resulted in earlier diagnoses and the rapid initiation of therapy, both of which are associated with favorable outcomes.
References
1.
UsmaniG.N., WodaB.A., NewburgerP.E.. Advances in understanding the pathogenesis of HLH.Br J Haematol.2013; 161(5): 609–622.
2.
LehmbergK., EhlS.. Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis.Br J Haematol.2013; 160(3): 275–287.
3.
MehtaR.S., SmithR.E.. Hemophagocytic lymphohistiocytosis (HLH): a review of literature.Med Oncol.2013; 30(4): 740.
HenterJ.I., ElinderG., OstA.; FHL Study Group of the Histiocyte Society. Diagnostic guidelines for hemophagocytic lymphohistiocytosis.Semin Oncol.1991; 18(1): 29–33.
KleynbergR.L., SchillerG.J.. Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy.Clin Adv Hematol Oncol.2012; 10(11): 726–732.
8.
AnsuiniV., RiganteD., EspositoS.. Debate around infection-dependent hemophagocytic syndrome in paediatrics.BMC Infect Dis.2013; 13: 15.
RosadoF.G., KimA.S.. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis.Am J Clin Pathol.2013; 139(6): 713–727.
11.
Alavi DarazamI., SamiR., GhadirM.. Hemophagocytic [corrected] lymphohistiocytosis associated with nephrotic syndrome and multi-organ failure.Iran J Kidney Dis.2012; 6(6): 467–469.
12.
AricoM., ImashukuS., ClementiR.. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene.Blood.2001; 97(4): 1131–1133.
13.
JordanM.B., AllenC.E., WeitzmanS.. How I treat hemophagocytic lymphohistiocytosis.Blood.2011; 118(15): 4041–4052.
14.
AllenC.E., YuX., KozinetzC.A., McClainK.L.. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis.Pediatr Blood Cancer.2008; 50(6): 1227–1235.
JankaG.E.. Familial and acquired hemophagocytic lymphohistiocytosis.Annu Rev Med.2012; 63: 233–246.
17.
HenterJ.I., ElinderG., SöderO.. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis.Acta Paediatr Scand.1991; 80(4): 428–435.
CréputC., GalicierL., BuyseS.. Understanding organ dysfunction in hemophagocytic lymphohistiocytosis.Intensive Care Med.2008; 34(7): 1177–1187.
20.
KrzewskiK., ColiganJ.E.. Human NK cell lytic granules and regulation of their exocytosis.Front Immunol.2012; 3: 335.
21.
FilipovichA.H.. Hemophagocytic lymphohistiocytosis (HLH) and related disorders.Hematol Am Soc Hematol Educ Prog.2009: 127–131.
22.
MénaschéG., FeldmannJ., FischerA.. Primary hemophagocytic syndromes point to a direct link between lymphocyte cytotoxicity and homeostasis.Immunol Rev.2005; 203: 165–179.
23.
BodeS.F., LehmbergK., Maul-PavicicA.. Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis.Arthritis Res Ther.2012; 14(3): 213.
24.
KompD.M., BuckleyP.J., McNamaraJ.. Soluble interleukin-2 receptor in hemophagocytic histiocytoses: searching for markers of disease activity.Pediatr Hematol Oncol.1989; 6(3): 253–264.
25.
BiondoC., SignorinoG., CostaA.. Recognition of yeast nucleic acids triggers a host-protective type I interferon response.Eur J Immunol.2011; 41(7): 1969–1979.
26.
BiondoC., MalaraA., CostaA.. Recognition of fungal RNA by TLR7 has a nonredundant role in host defense against experimental candidiasis.Eur J Immunol.2012; 42(10): 2632–2643.
27.
CostaA., GuptaR., SignorinoG.. Activation of the NLRP3 inflammasome by group B streptococci.Immunol J.2012; 188(4): 1953–1960.
28.
YangX., MiyawakiT., KaneganeH.. SAP and XIAP deficiency in hemophagocytic lymphohistiocytosis.Pediatr Int.2012; 54(4): 447–454.
29.
JordanM.B., HildemanD., KapplerJ.. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder.Blood.2004; 104(3): 735–743.
30.
UedaI., IshiiE., MorimotoA.. Correlation between phenotypic heterogeneity and gene mutational characteristics in familial hemophagocytic lymphohistiocytosis (FHL).Pediatr Blood Cancer.2006; 46(4): 482–488.
31.
SieniE., CeticaV., PiccinA.. Familial hemophagocytic lymphohistiocytosis may present during adulthood: clinical and genetic features of a small series.PLoS One.2012; 7: e44649.
32.
JankaG.. Hemophagocytic lymphohistiocytosis: when the immune system runs amok.Klin Padiatr.2009; 221(5): 278–285.
33.
ZhangK., JordanM.B., MarshR.A.. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH.Blood.2011; 118(22): 5794–5798.
34.
Zur StadtU., BeutelK., KolbergS.. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A.Hum Mutat.2006; 27(1): 62–68.
35.
SteppS.E., Dufourcq-LagelouseR., Le DeistF.. Perforin gene defects in familial hemophagocytic lymphohistiocytosis.Science.1999; 286(5446): 1957–1959.
36.
HorneA., RammeK.G., RuddE.. Characterization of PRF1, STX11 and UNC13D genotype-phenotype correlations in familial hemophagocytic lymphohistiocytosis.Br J Haematol.2008; 143(1): 75–83.
37.
FeldmannJ., CallebautI., RaposoG.. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3).Cell.2003; 115(4): 461–473.
38.
zur StadtU., SchmidtS., KasperB.. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11.Hum Mol Genet.2005; 14(6): 827–834.
ZhaoX.W., GazendamR.P., DrewniakA.. Defects in neutrophil granule mobilization and bactericidal activity in familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) syndrome caused by STXBP2/Munc18-2 mutations.Blood.2013; 122(1): 109–111.
de Saint BasileG., MénaschéG., FischerA.. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules.Nat Rev Immunol.2010; 10(8): 568–579.
44.
JankaG.E.. Familial and acquired hemophagocytic lymphohistiocytosis.Eur J Pediatr.2007; 166(2): 95–109.
45.
WeiM.L.. Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle function.Pigment Cell Res.2006; 19(1): 19–42.
46.
PagelJ., BeutelK., LehmbergK.. Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5).Blood.2012; 119(25): 6016–6024.
47.
SieniE., CeticaV., HackmannY.. Familial hemophagocytic lymphohistiocytosis: when rare diseases shed light on Immune system functioning.Front Immunol.2014; 5: 167.
BoxallS., McCormickJ., BeverleyP.. Abnormal cell surface antigen expression in individuals with variant CD45 splicing and histiocytosis.Pediatr Res.2004; 55(3): 478–484.
50.
FoxC.P., Shannon-LoweC., GothardP.. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells.Clin Infect Dis.2010; 51(1): 66–69.
51.
ChenC.J., HuangY.C., JaingT.H.. Hemophagocytic syndrome: a review of 18 pediatric cases.J Microbiol Immunol Infect.2004; 37(3): 157–163.
52.
ElazaryA.S., WolfD.G., AmirG.. Severe Epstein-Barr virus-associated hemophagocytic syndrome in six adult patients.J Clin Virol.2007; 40(2): 156–159.
53.
TsengY.T., ShengW.H., LinB.H.. Causes, clinical symptoms, and outcomes of infectious diseases associated with hemophagocytic lymphohistiocytosis in Taiwanese adults.J Microbiol Immunol Infect.2011; 44(3): 191–197.
54.
AbdelkefiA., Ben JamilW., TorjmanL.. Hemophagocytic syndrome after hematopoietic stem cell transplantation: a prospective observational study.Int J Hematol.2009; 89(3): 368–373.
55.
AlbrechtH., SchäferH., StellbrinkH.J.. Epstein-Barr virus–associated hemophagocytic syndrome. A cause of fever of unknown origin in human immunodeficiency virus infection.Arch Pathol Lab Med.1997; 121(8): 853–858.
56.
FardetL., BlumL., KerobD.. Human herpesvirus 8-associated hemophagocytic lymphohistiocytosis in human immunodeficiency virus-infected patients.Clin Infect Dis.2003; 37(2): 285–291.
57.
YilmazS., OrenH., DemircioğluF.. Parvovirus B19: a cause for aplastic crisis and hemophagocytic lymphohistiocytosis.Pediatr Blood Cancer.2006; 47(6): 861.
58.
ArdalanM.R., ShojaM.M., TubbsR.S.. Postrenal transplant hemophagocytic lymphohistiocytosis and thrombotic microangiopathy associated with parvovirus b19 infection.Am J Transplant.2008; 8(6): 1340–1344.
59.
HenterJ.I., ChowC.B., LeungC.W.. Cytotoxic therapy for severe avian influenza A (H5N1) infection.Lancet.2006; 367(9513): 870–873.
60.
WatanabeM., ShibuyaA., OkunoJ.. Hepatitis A virus infection associated with hemophagocytic syndrome: report of two cases.Intern Med.2002; 41(12): 1188–1192.
61.
SharpT.M., GaulL., MeuhlenbachsA.; Centers for Disease Control and Prevention. Fatal hemophagocytic lymphohistiocytosis associated with locally acquired dengue virus infection - New Mexico and Texas, 2012.MMWR Morb Mortal Wkly Rep.2014; 63(3): 49–54.
62.
DemircioğluF., KazanciE., GençD.B.,. H1N1 infection-related hemophagocytic lymphohistiocytosis in a child.Turk J Haematol.2013; 30(4): 426–428.
63.
AtteritanoM., DavidA., BagnatoG.. Haemophagocytic syndrome in rheumatic patients. A systematic review.Eur Rev Med Pharmacol Sci.2012; 16(10): 1414–1424.
64.
VellaJ.E., El-DalyH.. Hemophagocytic lymphohistiocytosis in a patient with angioimmunoblastic lymphoma: a case report and review of the literature.Int J Surg Pathol.2012; 20(6): 606–609.
65.
WeitzmanS.. Approach to hemophagocytic syndromes.Hematology Am Soc Hematol Educ Program.2011; 2011: 178–183.
66.
AlomariA., HuiP., XuM.. Composite peripheral T-cell lymphoma not otherwise specified, and B-cell small lymphocytic lymphoma presenting with hemophagocytic lymphohistiocytosis.Int J Surg Pathol.2013; 21(3): 303–308.
67.
TakahashiN., MiuraI., ChubachiA.. A clinicopathological study of 20 patients with T/natural killer (NK)-cell lymphoma-associated hemophagocytic syndrome with special reference to nasal and nasal-type NK/T-cell lymphoma.Int J Hematol.2001; 74(3): 303–308.
68.
KrenovaZ., SterbaJ., BlatnyJ.. A case of anaplastic large cell lymphoma- induced hemophagocytic lymphohistiocytosis in an adolescent female.Pediatr Blood Cancer.2007; 49(7): 1056.
69.
CzuchlewskiD.R., OupadiaS.L., ZhangQ.Y.. Diffuse large B-cell lymphoma with florid hemophagocytosis.Int J Hematol.2009; 89(1): 1–2.
70.
PasqualiniC., JoriniM., CarloniI.. Cytophagic histiocytic panniculitis, hemophagocytic lymphohistiocytosis and undetermined autoimmune disorder: reconciling the puzzle.Ital J Pediatr.2014; 40(1): 17.
71.
ChanK., BehlingE., StrayerD.S.. Prolonged hemophagocytic lymphohistiocytosis syndrome as an initial presentation of Hodgkin lymphoma: a case report.J Med Case Rep.2008; 2: 367.
72.
ChakerL., SegerenC.M., BotF.J.. Haemophagocytic syndrome and Hodgkin's disease variant of Richter's syndrome after fludarabine for CLL.Eur J Haematol.2010; 85(1): 91–92.
73.
AlaviS., EbadiM., JenabzadehA.. Hemophagocytic lymphohistiocytosis complicating erythroleukemia in a child with monosomy 7: a case report and review of the literature.Case Rep Hematol.2013; 2013: 581073.
74.
DelavigneK., BérardE., BertoliS.. Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy.Haematologica.2014; 99(3): 474–480.
AricòM., JankaG., FischerA.; FHL Study Group of the Histiocyte Society. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry.Leukemia.1996; 10(2): 197–203.
BhasinA., TolanR.W.. Hemophagocytic lymphohistiocytosis–a diagnostic dilemma: two cases and review.Clin Pediatr (Phila).2013; 52(4): 297–301.
79.
BehrensE.M., BeukelmanT., PaesslerM.. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.J Rheumatol.2007; 34(5): 1133–1138.
80.
VastertS.J., van WijkR., D'UrbanoL.E.. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis.Rheumatology (Oxford).2010; 49(3): 441–449.
81.
BehrensE.M., CannaS.W., SladeK.. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.J Clin Invest.2011; 121(6): 2264–2277.
82.
Pachlopnik SchmidJ., HoC.H., ChrétienF.. Neutralization of IFN gamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice.EMBO Mol Med.2009; 1(2): 112–124.
83.
SepulvedaF.E., DebeurmeF., MénaschéG.,. Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11.Blood.2013; 121(4): 595–603.
84.
TamuraM., GuJ., DanenE.H.. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway.J Biol Chem.1999; 274(29): 20693–20703.
85.
HenterJ.I., HorneA., AricóM.,. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.Pediatr Blood Cancer.2007; 48(2): 124–131.
86.
HenterJ.I., AricòM., EgelerR.M.. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society.Ped Pediatr Oncol.1997; 28(5): 342–347.
87.
GoelS., PolskiJ.M., ImranH.. Sensitivity and specificity of bone marrow hemophagocytosis in hemophagocytic lymphohistiocytosis.Ann Clin Lab Sci.2012; 42(1): 21–25.
JenkinsR.W., ClarkeC.J., LucasJ.T.. Evaluation of the role of secretory sphingomyelinase and bioactive sphingolipids as biomarkers in hemophagocytic lymphohistiocytosis.Am J Hematol.2013; 88(11): E265–72.
90.
FadeelB., OrreniusS., HenterJ.I.. Familial hemophagocytic lymphohistiocytosis: too little cell death can seriously damage your health.Leuk Lymphoma.2001; 42 (1-2): 13–20.
91.
BrycesonY.T., PendeD., Maul-PavicicA.. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes.Blood.2012; 119(12): 2754–2763.
92.
CôteM., MénagerM.M., BurgessA.. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells.J Clin Invest.2009; 119(12): 3765–3773.
93.
TitzeU., JankaG., SchneiderE.M.. Hemophagocytic lymphohistiocytosis and Kawasaki disease: combined manifestation and differential diagnosis.Pediatr Blood Cancer.2009; 53(3): 493–495.
94.
BodeS.F., BogdanC., BeutelK.. Hemophagocytic lymphohistiocytosis in imported pediatric visceral leishmaniasis in a nonendemic Area.J Pediatr.2014; 165(1): 147–153.
95.
AricòM., AllenM., BrusaS.. Haemophagocytic lymphohistiocytosis: proposal of a diagnostic algorithm based on perforin expression.Br J Haematol.2002; 119(1): 180–188.
ParizhskayaM., ReyesJ., JaffeR.. Hemophagocytic syndrome presenting as acute hepatic failure in two infants: clinical overlap with neonatal hemochromatosis.Pediatr Dev Pathol.1999; 2(4): 360–366.
98.
FardetL., GalicierL., LambotteO.. Development and validation of a score for the diagnosis of reactive hemophagocytic syndrome (HScore).Arthritis Rheumatol.2014; 66(9): 2613–2620.
99.
HenterJ.I., Samuelsson-HorneA., AricòM.,. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation.Blood.2002; 100(7): 2367–2373.
100.
CooperN., RaoK., GilmourK.. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis.Blood.2006; 107(3): 1233–1236.
101.
MarshR.A., VaughnG., KimM.O.. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation.Blood.2010; 116(26): 5824–5831.
ParkH.S., KimD.Y., LeeJ.H.. Clinical features of adult patients with secondary hemophagocytic lymphohistiocytosis from causes other than lymphoma: an analysis of treatment outcome and prognostic factors.Ann Hematol.2012; 91(6): 897–904.
105.
ChellapandianD., DasR., ZelleyK.. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.Br J Haematol.2013; 162(3): 376–382.
106.
MarshR.A., AllenC.E., McClainK.L.. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.Pediatr Blood Cancer.2013; 60(1): 101–109.
107.
MarshR.A., JordanM.B., FilipovichA.H.. Reduced-intensity conditioning haematopoietic cell transplantation for haemophagocytic lymphohistiocytosis: an important step forward.Br J Haematol.2011; 154(5): 556–563.
108.
StroutM.P., SeropianS., BerlinerN.. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis.Nat Rev Clin Oncol.2010; 7(7): 415–420.
109.
OdaY., UrushidaniY., OoiS.. Hemophagocytic lymphohistiocytosis in a rheumatoid arthritis patient treated with infliximab.Intern Med.2012; 51(6): 655–657.
110.
LacknerH., UrbanC., SovinzP.. Hemophagocytic lymphohistiocytosis as severe adverse event of antineoplastic treatment in children.Haematologica.2008; 93(2): 291–294.
111.
OlinR.L., NicholsK.E., NaghashpourM.. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis.Am J Hematol.2008; 83(9): 747–749.
TeacheyD.T., RheingoldS.R., MaudeS.L.. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.Blood.2013; 121(26): 5154–5157.
114.
JabadoN., de Graeff-MeederE.R., Cavazzana-CalvoM.. Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors.Blood.1997; 90(12): 4743–4748.
115.
QinQ., XieZ., ShenY.. Assessment of immunochemotherapy and stem cell transplantation on EBV-associated hemophagocytic lymphohistiocytosis in children: a systematic review and meta analysis.Eur Rev Med Pharmacol Sci.2012; 16(5): 672–678.
116.
SawadaA., OhgaS., IshiiE.. Feasibility of reduced-intensity conditioning followed by unrelated cord blood transplantation for primary hemophagocytic lymphohistiocytosis: a nationwide retrospective analysis in Japan.Int J Hematol.2013; 98(2): 223–230.
117.
YuJ.T., WangC.Y., YangY.. Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution.Ann Hematol.2013; 92(11): 1529–1536.
118.
TrottestamH., HorneA., AricòM.,. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol.Blood.2011; 118(17): 4577–4584.
119.
MahlaouiN., Ouachée-ChardinM., de Saint BasileG.. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients.Pediatrics.2007; 120(3): e622–628.
120.
OhgaS., KudoK., IshiiE.. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan.Pediatr Blood Cancer.2010; 54(2): 299–306.
121.
ShabbirM., LucasJ., LazarchickJ.. Secondary hemophagocytic syndrome in adults: a case series of 18 patients in a single institution and a review of literature.Hematol Oncol.2011; 29(2): 100–106.
122.
MachaczkaM., VaktnäsJ., KlimkowskaM.. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center.Leuk Lymphoma.2011; 52(4): 613–619.
123.
AlloryY., ChallineD., HaiounC.. Bone marrow involvement in lymphomas with hemophagocytic syndrome at presentation: a clinicopathologic study of 11 patients in a Western institution.Am J Surg Pathol.2001; 25(7): 865–874.
FaliniB., PileriS., De SolasI.. Peripheral T-cell lymphoma associated with hemophagocytic syndrome.Blood.1990; 75(2): 434–444.
127.
ParikhS.A., KapoorP., LetendreL.. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis.Mayo Clin Proc.2014; 89(4): 484–492.
128.
KogawaK., SatoH., AsanoT.. Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: report of the Japan Histiocytosis Study Group.Pediatr Blood Cancer.2014; 61(7): 1257–1262.
129.
DhoteR., SimonJ., PapoT.. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review.Arthritis Rheum.2003; 49(5): 633–639.
130.
FukayaS., YasudaS., HashimotoT.. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases.Rheumatology (Oxford).2008; 47(11): 1686–1691.
131.
ShuperA., AttiasD., KornreichL.. Familial hemophagocytic lymphohistiocytosis: improved neurodevelopmental outcome after bone marrow transplantation.J Pediatr.1998; 133(1): 126–128.
132.
KaitoK., KobayashiM., KatayamaT.. Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases.Eur J Haematol.1997; 59(4): 247–253.
133.
ImashukuS.. Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment.Int J Hematol.1997; 66(2): 135–151.
134.
TrottestamH., BerglöfE., HorneA.. Risk factors for early death in children with haemophagocytic lymphohistiocytosis.Acta Paediatr.2012; 101(3): 313–318.
